Raymond James & Associates’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-11,314
| Closed | -$1.95M | – | 4370 |
|
|
2021
Q3 | $1.95M | Sell |
11,314
-1,153
| -9% | -$151K | ﹤0.01% | 2122 |
|
|
2021
Q2 | $1.56M | Sell |
12,467
-1,509
| -11% | -$190K | ﹤0.01% | 2278 |
|
|
2021
Q1 | $1.9M | Buy |
13,976
+1,549
| +12% | +$200K | ﹤0.01% | 2053 |
|
|
2020
Q4 | $1.59M | Buy |
12,427
+1,574
| +15% | +$185K | ﹤0.01% | 2037 |
|
|
2020
Q3 | $1.22M | Buy |
10,853
+22
| +0.2% | +$2.19K | ﹤0.01% | 2058 |
|
|
2020
Q2 | $1.03M | Buy |
10,831
+4,038
| +59% | +$389K | ﹤0.01% | 2143 |
|
|
2020
Q1 | $610K | Sell |
6,793
-599
| -8% | -$46.6K | ﹤0.01% | 2288 |
|
|
2019
Q4 | $392K | Buy |
7,392
+17
| +0.2% | +$775 | ﹤0.01% | 2912 |
|
|
2019
Q3 | $291K | Sell |
7,375
-80
| -1% | -$3.47K | ﹤0.01% | 3028 |
|
|
2019
Q2 | $306K | Sell |
7,455
-1,843
| -20% | -$76.3K | ﹤0.01% | 3003 |
|
|
2019
Q1 | $433K | Buy |
9,298
+90
| +1% | +$3.95K | ﹤0.01% | 2760 |
|
|
2018
Q4 | $401K | Sell |
9,208
-147
| -2% | -$7.34K | ﹤0.01% | 2689 |
|
|
2018
Q3 | $535K | Sell |
9,355
-151
| -2% | -$7.42K | ﹤0.01% | 2662 |
|
|
2018
Q2 | $461K | Buy |
9,506
+28
| +0.3% | +$1.02K | ﹤0.01% | 2740 |
|
|
2018
Q1 | $371K | Buy |
9,478
+164
| +2% | +$6.97K | ﹤0.01% | 2754 |
|
|
2017
Q4 | $395K | Buy |
9,314
+728
| +8% | +$27.3K | ﹤0.01% | 2677 |
|
|
2017
Q3 | $320K | Sell |
8,586
-14
| -0.2% | -$486 | ﹤0.01% | 2750 |
|
|
2017
Q2 | $261K | Buy |
8,600
+1,017
| +13% | +$29.5K | ﹤0.01% | 2818 |
|
|
2017
Q1 | $201K | Buy |
+7,583
| New | +$200K | ﹤0.01% | 2933 |
|
Raymond James & Associates's XLRN Position: Q4 2021 in Review
Raymond James & Associates sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 11,314 shares — an estimated $1.95M sold.
Raymond James & Associates first reported a position in XLRN in Q1 2017 and held it in 19 quarters. The position peaked at $1.95M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Raymond James & Associates reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Raymond James & Associates sold 11,314 Acceleron Pharma shares in Q4 2021, an estimated $1.95M.
- Raymond James & Associates first reported a position in Acceleron Pharma in Q1 2017 and held it in 19 quarters.
- Raymond James & Associates's Acceleron Pharma position peaked at $1.95M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.